David Z Cherney

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11090894/publications.pdf

Version: 2024-02-01

41 papers	1,379 citations	361045 20 h-index	344852 36 g-index
41 all docs	41 docs citations	41 times ranked	1939 citing authors

#	Article	IF	Citations
1	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
2	A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812210812.	0.6	7
3	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. Acta Diabetologica, 2021, 58, 81-91.	1.2	24
4	Increased risk for microvascular complications among women with gestational diabetes in the third trimester The Microalbuminuria and Retinopathy in Gestational Diabetes (MARIGOLD) Study. Diabetes Research and Clinical Practice, 2021, 180, 109068.	1.1	3
5	SGLT2â€inhibition reverts urinary peptide changes associated with severe COVIDâ€19: An inâ€silico proofâ€ofâ€principle of proteomicsâ€based drug repurposing. Proteomics, 2021, 21, e2100160.	1.3	3
6	Evaluation of novel glomerular filtration rate estimation equations in adolescents and young adults with type 1 diabetes. Journal of Diabetes and Its Complications, 2021, 36, 108081.	1.2	5
7	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. Journal of Diabetes and Its Complications, 2020, 34, 107707.	1.2	22
8	Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 444-446.	2.2	5
9	Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812093570.	0.6	9
10	Use of sodiumâ€“glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. Cmaj, 2020, 192, E351-E360.	0.9	53
11	Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 285-288.	2.2	23
12	Renal physiology of glucose handling and therapeutic implications. Nephrology Dialysis Transplantation, 2020, 35, i3-i12.	0.4	46
13	Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 467-477.	0.4	3
14	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107397.	1.2	8
15	Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection. Journal of the American College of Cardiology, 2019, 74, 2511-2524.	1.2	54
16	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. Cmaj, 2019, 191, E1128-E1135.	0.9	17
17	Renal SGLT mRNA expression in human health and disease: a study in two cohorts. American Journal of Physiology - Renal Physiology, 2019, 317, F1224-F1230.	1.3	18
18	Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. Diabetes Care, 2019, 42, 2290-2297.	4.3	15

#	Article	IF	Citations
19	Mineralocorticoid Antagonism and Diabetic Kidney Disease. Current Diabetes Reports, 2019, 19, 4.	1.7	30
20	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. Diabetes Care, 2019, 42, 1716-1723.	4.3	10
21	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€"Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	4.3	39
22	Sodium transport in diabetes: two sides to the coin. Nature Reviews Nephrology, 2019, 15, 125-126.	4.1	5
23	Effects of the SGLTâ€2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes, Obesity and Metabolism, 2018, 20, 1988-1993.	2.2	180
24	The Physiological Rationale for Incorporating Pulsatility in Continuous-Flow Left Ventricular Assist Devices. Cardiology in Review, 2018, 26, 294-301.	0.6	10
25	Renal Hyperfiltration in Adolescents with Type 2 Diabetes: Physiology, Sex Differences, and Implications for Diabetic Kidney Disease. Current Diabetes Reports, 2018, 18, 22.	1.7	33
26	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes Care, 2018, 41, 88-95.	4.3	17
27	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care, 2018, 41, 2560-2569.	4.3	239
28	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2018, 32, 660-664.	1.2	22
29	Social Determinants of Health Are Associated with Markers of Renal Injury in Adolescents with Type 1 Diabetes. Journal of Pediatrics, 2018, 198, 247-253.e1.	0.9	14
30	Neurohormone levels remain elevated in continuous flow left ventricular assist device recipients. Journal of Cardiac Surgery, 2018, 33, 403-411.	0.3	6
31	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. PLoS ONE, 2018, 13, e0196647.	1.1	13
32	Assessment of urinary microparticles in normotensive patients with type 1 diabetes. Diabetologia, 2017, 60, 581-584.	2.9	65
33	New therapy, new challenges: The effects of long-term continuous flow left ventricular assist device on inflammation. International Journal of Cardiology, 2016, 215, 424-430.	0.8	26
34	Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies. Current Diabetes Reports, 2016, 16, 11.	1.7	28
35	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. Diabetes Care, 2016, 39, e67-e68.	4.3	19
36	Renal Function Is Associated With Peak Exercise Capacity in Adolescents With Type 1 Diabetes. Diabetes Care, 2015, 38, 126-131.	4.3	22

#	Article	IF	Citations
37	Longitudinal Assessment of Inflammation in Recipients of Continuous-Flow Left Ventricular Assist Devices. Canadian Journal of Cardiology, 2015, 31, 348-356.	0.8	34
38	Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrology Dialysis Transplantation, 2015, 30, 1706-1711.	0.4	88
39	Fat Mass Is Associated With Cystatin C and Estimated Glomerular Filtration Rate in Adolescents With Type 1 Diabetes. , 2015, 25, 454-455.		0
40	Insulin Sensitivity Is an Important Determinant of Renal Health in Adolescents With Type 2 Diabetes. Diabetes Care, 2014, 37, 3033-3039.	4.3	41
41	A Physiological Analysis of Hyponatremia: Implications for Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2001, 21, 1-9.	1.1	26